Thrive Earlier Detection Closes $257 Million Series B Financing

Catalent Enters Into Strategic Partnership With Editas Medicine To Support Gene Editing Medicine Pipeline

Bristol Myers Squibb and bluebird bio Announce Submission of Biologics License Application (BLA) to FDA for Idecabtagene Vicleucel (Ide-cel, bb2121) for Adults with Relapsed and Refractory Multiple Myeloma

Rhythm Pharmaceuticals Announces Appointment of Joseph Shulman as Senior Vice President of Technical Operations

Editas Medicine Appoints Gad Berdugo As Chief Business Officer

Allena Pharmaceuticals Announces $5.0 Million Bought Deal Offering

Allena Pharmaceuticals Increases Previously Announced Bought Deal to $6.7 Million

Blueprint Medicines Receives Positive CHMP Opinion for Avapritinib for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumors

Blueprint Medicines to Report Second Quarter 2020 Financial Results on Thursday, July 30, 2020

Editas Medicine To Host Conference Call Discussing Second Quarter 2020 Results And Corporate Update

MyoKardia Announces Receipt of Breakthrough Therapy Designation from FDA for Mavacamten for the Treatment of Symptomatic, Obstructive Hypertrophic Cardiomyopathy

Nurix Therapeutics Announces Pricing of $209 Million Initial Public Offering

MyoKardia and Fulcrum Therapeutics Announce Multi-Target Collaboration to Discover Novel Targeted Therapies for Genetic Cardiomyopathies

Sage Therapeutics to Report Second Quarter 2020 Financial Results on Monday, August 10, 2020

Relay Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Rhythm Pharmaceuticals Announces Appointment of David Meeker, M.D., as Chief Executive Officer

Agios to Webcast Conference Call of Second Quarter 2020 Financial Results on July 30, 2020

Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide in Bardet-Biedl Syndrome in Diabetes, Obesity and Metabolismr

Relay Therapeutics Announces Pricing of Initial Public Offering

Blueprint Medicines Announces Global Collaboration with Roche to Develop and Commercialize Pralsetinib for Patients with RET-Altered Cancers

Nurix Therapeutics Announces Addition of Dr. Jason Kantor to its Management Team

Editas Medicine And Azzur Group Announce A Multi-Year Agreement For EDIT-301 And EDIT-201 Manufacturing

MyoKardia Announces Appointment of Denelle J. Waynick as General Counsel and Corporate Secretary

Rhythm Pharmaceuticals Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Setmelanotide for Treatment of POMC and LEPR Deficiency Obesities

Rhythm Pharmaceuticals Announces Submission of Marketing Authorization Application to the European Medicines Agency for Setmelanotide in POMC and LEPR Deficiency Obesities

Celsius Therapeutics Signs Research Agreements with Leading Academic Centers to Develop Insights into Inflammatory Bowel Disease Biology

Blueprint Medicines Announces Submission of New Drug Application to FDA for Pralsetinib for the Treatment of Advanced RET Mutant and RET Fusion-Positive Thyroid Cancers

Revolution Medicines Reports New Application of Tri-Complex Modality for “Undruggable” Protein Targets and Announces License to Ginkgo Bioworks to Explore Potential Use Against Novel Coronavirus

Goldfinch Bio Secures $100 Million in Series B Financing

Blueprint Medicines Announces Publication in The Lancet Oncology Showing Durable Clinical Benefits of AYVAKIT™ (avapritinib) in NAVIGATOR Trial Patients with PDGFRA D842V Mutant GIST

Nurix Therapeutics Announces Formation Of DeCART Therapeutics To Advance New CAR T Therapies Using Targeted Protein Modulation

GBT Awards $250,000 in ACCEL Grants to Advance Access to Care for People Living with Sickle Cell Disease

GBT Announces Plans to Seek Regulatory Approval for Oxbryta® (voxelotor) to Treat Sickle Cell Patients in Europe

Fulcrum Therapeutics Announces Initiation of Multi-Center Phase 3 (LOSVID) Trial with Losmapimod for Hospitalized COVID-19 Patients

CytomX Therapeutics Announces Preclinical Data from Anti-CTLA-4 Probody Therapeutic Programs Presented by Partner Bristol Myers Squibb at AACR Annual Meeting

Jounce Therapeutics Presents First Preclinical Data on Anti-CCR8 Antibody JTX-1811 and Vopratelimab Translational Data at The American Association for Cancer Research Virtual Annual Meeting

MyoKardia Announces Danicamtiv Data Presentation at the European Society of Cardiology’s Virtual Heart Failure Association Discoveries

Revolution Medicines Appoints Eric T. Schmidt, Ph.D. and Peter Svennilson to its Board of Directors

Agios to Present at the BMO 2020 Prescriptions for Success Healthcare Virtual Conference on Tuesday, June 23, 2020

FoundationOne®CDx Receives FDA Approval as the First Companion Diagnostic to Identify Advanced Cancer Patients with Solid Tumors that are Tumor Mutational Burden-High (TMB-H) and Appropriate for Immunotherapy Treatment with KEYTRUDA® (pembrolizumab)

MyoKardia to Present at Virtual BMO 2020 Prescriptions for Success Healthcare Conference

Nurix Therapeutics Announces Addition Of Immuno-Oncology Clinical Experts To Its Management Team

Foundation Medicine Appoints Dr. Geoffrey Oxnard as Vice President, Global Medical Lead, Liquid Franchise

Magenta Therapeutics And Beam Therapeutics Announce Collaboration To Evaluate Targeted Antibody-Drug Conjugate (ADC) MGTA-117 As Conditioning Regimen For Base Editing Therapies

Agios Announces Clinical Proof-of-Concept Has Been Established in Phase 1 Study of Mitapivat, First-in Class PKR Activator, in Sickle Cell Disease

Agios First-in Class PKR Activator Mitapivat Demonstrates Sustained Hemoglobin Responses in Non-transfusion-dependent α- and β-Thalassemia in Phase 2 Study

Majority of Evaluable Patients Across Genotypes Achieve Transfusion Independence and Maintain It with Near-Normal Hemoglobin Levels in Phase 3 Studies of betibeglogene autotemcel (LentiGlobin™ for β-thalassemia) Gene Therapy Presented at EHA Congress

New Data Show Near Elimination of Sickle Cell Disease-Related Vaso-Occlusive Crises and Acute Chest Syndrome in Phase 1/2 Clinical Study of bluebird bio’s LentiGlobin™ Gene Therapy for Sickle Cell Disease at 25th EHA Congress

Constellation Pharmaceuticals Provides Updates of MANIFEST Study for CPI-0610 and EZH2 Franchise

Agios and Royalty Pharma Announce $255 Million Purchase Agreement for IDHIFA® Royalty